Efficacy and safety of Mudan granules for treatment of diabetic peripheral neuropathy: a multicenter, double-blind, placebo-controlled, randomized, clinical trial.

J EthnopharmacolApr 30, 2026 (epub)
Clinical ResearchNeurologyEndocrinology

De Jin, Qing Gao, Yuehong Zhang et al.

✦ AI-curated · Sources linked

In 30 seconds

This multicenter, double-blind, placebo-controlled randomized trial evaluated the efficacy and safety of Mudan granules in 400 patients with diabetic peripheral neuropathy (DPN). After 24 weeks, the Mudan group showed a significant improvement in the Michigan Diabetic Neuropathy Score (MDNS) with a mean change of -4.80 compared to -2.66 in the control group.

Key findings

  • The mean change in MDNS was -4.80 for the Mudan group versus -2.66 for the control group.
  • The least squares mean MDNS change was -4.74 for Mudan and -2.72 for placebo.
  • A statistically significant difference in MDNS improvement was observed between the two groups.

Why it matters

The study provides evidence that Mudan granules may effectively alleviate symptoms of diabetic peripheral neuropathy, a common complication of diabetes that significantly impacts quality of life. Understanding new treatment options is essential for managing this condition.

Source

Published in J Ethnopharmacol. This summary was written by xxcode from the publication's abstract and metadata. It is not peer reviewed and is not a substitute for the original article. For clinical decisions, review the original publication.

ShareTelegramLinkedIn

AI-generated summaries may contain errors or omissions. Verify clinically important information with the original publication.

More in Neurology

Want this personalized?

Stop searching the literature. Choose what you follow and xxcode will build your personalized medical digest.

  • Your specialties
  • Your filters and thresholds
  • Clinical Research + Case Reports, tuned separately
  • Automatic weekly delivery
  • Audio and text

Prefer listening? Personalized audio digests are available with Pro.

Stay updated for free

Get the 3 most interesting publications in one specialty each week.

Weekly email. Unsubscribe anytime.